GreenDroitin for Dogs — Plant-Based Chondroitin Alternative for Joint Health

· by Glendon Lloyd Dip.Canine.Nutrition Dip.Dog.Nutrigenomics

GreenDroitin® for Dogs — Plant-Based Chondroitin Alternative for Joint Health

GreenDroitin® – Osteoarthritis Support for Dogs

Summary

For decades, chondroitin sulphate has been one of the most widely used joint-support ingredients for dogs with osteoarthritis — and for good reason. As a foundational structural molecule in cartilage, chondroitin provides elasticity, water retention and resistance to compression, making it essential for healthy joint function. In canine clinical trials, glucosamine–chondroitin supplementation has demonstrated statistically significant improvements in pain scores, weight-bearing and overall clinical condition.¹ But the conventional animal-derived sources come with significant drawbacks — which is exactly why GreenDroitin® for dogs represents such an important development.

The problem has always been the source. Conventional chondroitin sulphate is extracted from animal cartilage — primarily bovine trachea, porcine cartilage and shark cartilage — raising significant ethical, sustainability and quality-consistency concerns. Shark cartilage harvesting contributes to the depletion of global shark populations. Bovine and porcine sources carry potential contamination risks, batch-to-batch variability and are unsuitable for dogs with animal protein sensitivities.

GreenDroitin® represents a fundamental shift. Manufactured by Vivatis Pharma GmbH (Hamburg, Germany), GreenDroitin® is a plant-derived chondroitin sulphate extracted from Tremella fuciformis — the snow fungus — through a patented, controlled extraction process that yields a low-molecular-weight chondroitin sulphate with a unique chemical-biological profile.² Peer-reviewed in vitro research published in the Journal of Functional Foods has demonstrated that GreenDroitin® crosses the intestinal barrier more effectively than conventional animal-derived chondroitin sources, exerts protective effects on chondrocytes under osteoarthritis conditions, and modulates ADAMTS-5 enzyme activity to help prevent cartilage degradation.²

This guide examines the evidence behind GreenDroitin® — from its source organism and production process to its bioactive composition, efficacy data and safety profile — and explains why Bonza selected this ingredient for its Bounce and Boost joint-support formulations.

Key Takeaways

  • GreenDroitin® is a plant-derived chondroitin sulphate extracted from Tremella fuciformis (snow fungus) by Vivatis Pharma GmbH, offering an ethical, sustainable and vegan alternative to animal-sourced chondroitin.²
  • In vitro research using 3D intestinal organoid models demonstrated that GreenDroitin® achieves superior intestinal absorption compared with conventional animal-derived chondroitin sulphate sources.²
  • GreenDroitin® exhibited chondroprotective effects in an in vitro osteoarthritis model, including modulation of ADAMTS-5 (a key cartilage-degrading enzyme) to help prevent cartilage breakdown.²
  • The low molecular weight profile of GreenDroitin® contributes to its enhanced bioavailability, with the manufacturer reporting effective results at approximately one-third of the dose required by conventional chondroitin sources.³
  • Tremella fuciformis polysaccharides have independently demonstrated anti-inflammatory, antioxidant and immunomodulatory properties in multiple peer-reviewed studies — providing additional biological value beyond conventional chondroitin sulphate alone.⁴ ⁵
  • Bonza Bounce contains 80 mg of chondroitin sulphate from GreenDroitin® per chewy, while Bonza Boost contains 45 mg per chewy — both as part of comprehensive multi-pathway joint-support formulations.³
  • No canine-specific clinical trials on GreenDroitin® have been published to date; current evidence is drawn from in vitro studies, translational research on Tremella fuciformis polysaccharides, and the established clinical evidence base for chondroitin sulphate in dogs.
  • Chondroitin sulphate also functions as a prebiotic-like substrate in the gut, connecting joint supplementation to the gut–joint axis — the emerging science linking gut health to systemic inflammation and joint outcomes.⁶ ⁷

In this guide:

What Is GreenDroitin®?

GreenDroitin® is a registered trademark ingredient manufactured by Vivatis Pharma GmbH, a pharmaceutical and nutraceutical raw materials company headquartered in Hamburg, Germany. It is classified as a plant-derived chondroitin sulphate, produced through a controlled extraction process from the edible fungus Tremella fuciformis — commonly known as snow fungus or silver ear mushroom.²

To understand what makes GreenDroitin® significant, it helps to first understand what conventional chondroitin sulphate is and why its traditional sources present challenges.

Chondroitin sulphate: the molecule

Chondroitin sulphate (CS) is a naturally occurring sulphated glycosaminoglycan (GAG) composed of repeating disaccharide units of N-acetylgalactosamine and glucuronic acid. In the body, it is a major structural component of articular cartilage, where it contributes to water retention, compressive resistance and elasticity — the properties that allow joints to absorb shock and maintain smooth, pain-free movement.⁸ Chondroitin also serves structural and protective roles in bone, skin, tendons, ligaments, the bladder wall and the intestinal mucosa.

The problem with animal-derived sources

Traditionally, supplemental chondroitin sulphate has been extracted from bovine trachea, porcine cartilage and shark cartilage. These sources present several challenges. The global demand for shark cartilage has contributed to significant depletion of shark populations — an ecological concern that extends beyond individual species to the health of entire marine ecosystems.⁹ Bovine and porcine sources carry risks of contamination with prions, heavy metals or pharmaceutical residues, and the chondroitin content of animal cartilage can vary significantly between batches, making standardisation difficult.⁹ For dogs with animal protein sensitivities or allergies, animal-derived chondroitin may also introduce unwanted antigenic material.

How GreenDroitin® differs

GreenDroitin® addresses these limitations by deriving chondroitin sulphate from a fungal source rather than animal cartilage. Tremella fuciformis is a well-characterised edible fungus with a long history of use in traditional Chinese medicine and East Asian cuisine. It is naturally rich in polysaccharides that include glycosaminoglycan-like structures — the same class of molecules to which chondroitin sulphate belongs.²

Structurally, GreenDroitin® is characterised as a low-molecular-weight chondroitin sulphate with a heterogeneous chemical-biological profile.² This is an important distinction from conventional animal-derived CS, which tends to have higher and more variable molecular weights. The lower molecular weight of GreenDroitin® is directly linked to its enhanced intestinal absorption — a critical factor in oral supplementation, where bioavailability has historically been a limiting factor for chondroitin efficacy.²

The extraction and production process is covered by patents (WO/2020/245809 and WO2021/250566A1) held by Vivatis Pharma, which describe processes for extracting both hyaluronic acid and chondroitin sulphate from Tremella fuciformis without requiring bacterial fermentation or digestion — distinguishing GreenDroitin® from biotechnological chondroitin alternatives that use bacterial synthesis.¹⁰

How Is GreenDroitin® Produced?

Source organism

Tremella fuciformis (Berk. 1856) belongs to the family Tremellaceae within the division Basidiomycota. It is a jelly fungus that originates in tropical and subtropical regions, where it naturally grows on dead hardwood logs. Due to extremely high demand — both for culinary and medicinal applications — it is now extensively cultivated commercially, primarily in greenhouse environments.¹⁰

The fungus is rich in polysaccharides whose backbone structure consists of (1→3)-α-D-mannan chains with side chains including glucuronic acid, xylose and fucose.⁴ This polysaccharide architecture naturally contains glycosaminoglycan-like structural motifs, making Tremella fuciformis a viable biological source for extracting CS-equivalent molecules.

Extraction process

According to the published patent documentation, GreenDroitin® is produced through a controlled extraction process that isolates chondroitin sulphate from the fungal biomass.¹⁰ The process does not involve bacterial fermentation or enzymatic digestion with bacteria — a distinction from some other non-animal chondroitin production methods (such as Mythocondro®, which uses E. coli fermentation). Instead, the extraction relies on physical and chemical separation techniques applied directly to the fungal starting material.

The result is a low-molecular-weight chondroitin sulphate (weight average molecular weight in the range of 1–50 kDa according to the patent specifications) with a consistent quality profile.¹⁰ This molecular weight range is substantially lower than conventional animal-derived CS, which typically ranges from 15–50 kDa or higher depending on the source and extraction method.

Sustainability and ethical advantages

The environmental and ethical benefits of fungal-derived chondroitin over animal sources are considerable. Tremella fuciformis is a rapidly renewable resource that can be cultivated year-round in controlled greenhouse environments, with minimal ecological impact compared to shark harvesting or livestock-dependent supply chains. Production does not require animal slaughter, making it suitable for vegan and vegetarian formulations. The supply chain is more predictable and controllable than animal-derived sources, where batch quality depends on the animal’s age, health, diet and cartilage tissue processing conditions.

Quality control and standardisation

One of the persistent challenges with animal-derived chondroitin sulphate supplements has been quality variability. Independent analyses have repeatedly found that many commercial CS supplements contain less chondroitin than claimed on the label, with some products containing significant quantities of other glycosaminoglycans or impurities.⁸ Because GreenDroitin® is produced through a controlled, patented extraction process from a cultivated source, it offers inherent advantages in batch consistency and standardisation — a critical factor when the purity of chondroitin sulphate directly influences its therapeutic efficacy.

Bioactive Composition

Glycosaminoglycan profile

The Galla et al. (2022) study, published in the Journal of Functional Foods, conducted detailed chemical characterisation of GreenDroitin® and found that it exhibits a heterogeneous chemical-biological profile.² This heterogeneity — meaning the presence of multiple molecular species within the extract rather than a single uniform compound — may actually be advantageous. The researchers noted that this diverse profile may be responsible for the range of biological functions observed in their in vitro experiments, including superior intestinal absorption and chondroprotective effects.²

Low molecular weight

The defining chemical characteristic of GreenDroitin® is its low molecular weight compared with conventional animal-derived CS. This is clinically significant because molecular weight is one of the primary determinants of oral bioavailability for glycosaminoglycans. Larger CS molecules are poorly absorbed across the intestinal barrier, which is why conventional chondroitin sulphate has an estimated oral bioavailability of only 5–15% in dogs.⁸ ¹¹ The lower molecular weight of GreenDroitin® enables more efficient transport across the intestinal epithelium, as demonstrated in the 3D organoid absorption studies.²

GreenDroitin Plant-based Chondroitin Sulphate Absorption Rates vs Animal-based Chondroitin

Beyond conventional CS: the Tremella fuciformis advantage

An important distinction between GreenDroitin® and conventional animal-derived CS is that the fungal extract carries additional bioactive properties inherent to Tremella fuciformis polysaccharides. These polysaccharides have been independently studied and found to possess anti-inflammatory, antioxidant, immunomodulatory, neuroprotective and gut microbiome-modulatory properties.⁴ ⁵ ¹²

Specifically, Tremella fuciformis polysaccharides have been shown to attenuate oxidative stress and inflammatory responses in macrophages by inhibiting NF-κB nuclear translocation, suppressing the Akt and p38MAPK signalling pathways, and reducing production of pro-inflammatory cytokines including TNF-α and IL-6.⁵ In a colitis model, high-dose Tremella fuciformis polysaccharides stimulated regulatory Foxp3+ T cells, promoted anti-inflammatory cytokine production, and restored gut microbial diversity — including increasing the relative abundance of beneficial Lactobacillus populations.¹²

These properties mean that GreenDroitin® may offer biological value beyond what conventional chondroitin sulphate alone provides — though it is important to note that the specific polysaccharide fractions responsible for these effects may differ from the CS fraction, and the degree to which these additional bioactivities are preserved in the final GreenDroitin® extract has not been fully characterised in published literature.

Evidence-Based Efficacy

The Galla et al. (2022) study: the core evidence

The primary published evidence for GreenDroitin® comes from a peer-reviewed study by Galla, Ruga, Ferrari, Saccone, Saccuman, Invernizzi and Uberti, published in the Journal of Functional Foods in November 2022.² This study investigated the biological effects of GreenDroitin® across two key experimental domains: intestinal absorption and chondroprotective activity in osteoarthritis conditions.

Intestinal absorption. The researchers used a sophisticated 3D intestinal organoid system — a model approved by both the FDA and EFSA for simulating the human intestinal environment — to compare the absorption of GreenDroitin® with commercially available chondroitin sulphate from animal sources. The results demonstrated that GreenDroitin® achieves a higher rate of absorption through the intestinal barrier than its animal-derived comparators, without compromising the integrity of the intestinal barrier itself.² This is a particularly important finding because some compounds that cross the intestinal barrier do so by disrupting tight junctions — which would be counterproductive for gut health. GreenDroitin® passed through without causing such disruption.

Chondroprotective effects. Using an in vitro osteoarthritis model with human chondrocytes, the study demonstrated that GreenDroitin® exerts beneficial effects on chondrocyte activity under both normal and osteoarthritis conditions.² Critically, GreenDroitin® was found to modulate the expression of ADAMTS-5 — a disintegrin and metalloproteinase with thrombospondin motifs that is one of the principal enzymes responsible for the degradation of aggrecan, the major proteoglycan in cartilage. Inhibition of ADAMTS-5 is considered one of the most clinically relevant mechanisms by which chondroitin sulphate protects against cartilage breakdown in osteoarthritis.²

The study concluded that GreenDroitin® can be considered a promising nutraceutical candidate for oral intake, based on its combination of superior absorption, intestinal barrier safety and chondroprotective activity.²

Tremella fuciformis polysaccharides: supporting evidence

While the Galla et al. study provides the direct evidence base for GreenDroitin® as a finished ingredient, a substantial body of research on Tremella fuciformis polysaccharides (TFPs) provides broader scientific context for the parent compound.

Tan et al. (2024) investigated the proliferative and anti-inflammatory effects of Tremella fuciformis polysaccharides on human chondrocytes (T/C-28a2 cell line) in an osteoarthritis model.¹³ The study found that TFPs promoted chondrocyte proliferation without cytotoxicity, reduced secretion of IL-6 (a key inflammatory cytokine), upregulated osteoprotegerin (OPG — a protein that protects against bone and cartilage destruction), and downregulated pro-apoptotic protein Bax, the ERK-MAPK signalling pathway and NF-κB. TFPs also inhibited intracellular reactive oxygen species (ROS) levels.¹³ These findings directly support the relevance of Tremella fuciformis-derived compounds for joint health applications.

A comprehensive review by Rui et al. (2025), published in the Journal of Food Science, summarised the extensive evidence base for TFPs, confirming their antioxidant, anti-tumour, immunomodulatory, memory-enhancing, anti-inflammatory, hypoglycaemic and hypolipidaemic properties, along with skin-protective effects and gut microbiota modulation.⁴

The established evidence base for chondroitin sulphate in dogs

It is important to contextualise GreenDroitin® within the broader evidence base for chondroitin sulphate in canine osteoarthritis, since GreenDroitin® delivers the same core molecule — CS — through a different source.

The landmark canine study by McCarthy et al. (2007) — a randomised, double-blind, positive-controlled trial — demonstrated that dogs receiving oral glucosamine HCl with chondroitin sulphate showed statistically significant improvements in pain, weight-bearing and overall clinical condition by day 70 (p < 0.001), with efficacy comparable to carprofen.¹ This remains the most frequently cited positive canine clinical trial for glucosamine–chondroitin supplementation.

Segarra et al. (2016) conducted a randomised, placebo-controlled trial investigating an oral supplement containing chondroitin sulphate and prebiotics for canine inflammatory bowel disease (IBD).⁶ While the study was underpowered for some endpoints, it demonstrated the safety and tolerability of oral CS supplementation in dogs over 180 days and provided evidence for improvements in serum biomarkers of inflammation and oxidative stress.⁶

A systematic review by Bhathal et al. (2017) in Open Veterinary Journal critically appraised the available clinical evidence, noting that while results are promising, the evidence base remains limited by small sample sizes, methodological variability and the slow onset of action of these nutraceuticals.¹⁴ The review highlighted the need for larger, longer-duration trials with objective outcome measures.

Honest assessment of evidence gaps

Transparency about the current state of the evidence is essential. The direct evidence for GreenDroitin® specifically is currently limited to the Galla et al. (2022) in vitro study.² No canine-specific clinical trials using GreenDroitin® have been published. No head-to-head in vivo trials comparing GreenDroitin® with animal-derived chondroitin in dogs exist in the published literature.

The in vitro demonstration of superior absorption and chondroprotective activity is scientifically meaningful and was conducted using validated models, but in vitro findings do not always translate directly to clinical outcomes in living animals. The manufacturer’s claim that GreenDroitin® achieves effective results at approximately one-third of the dose of conventional CS sources is based on the absorption data and has not been validated through comparative dose-finding studies in dogs.³

What can be said with confidence is that GreenDroitin® delivers chondroitin sulphate — a molecule with an established (if debated) evidence base in canine joint health — through a source that offers demonstrated advantages in intestinal absorption, quality consistency and ethical sourcing. The additional bioactive properties of Tremella fuciformis polysaccharides provide a scientifically plausible basis for benefits beyond conventional CS, but these require further in vivo validation.

Joint Health and the Gut–Joint Axis

The connection between gut health and joint health is one of the most significant developments in veterinary nutritional science. The gut–joint axis describes the bidirectional relationship between the intestinal microbiome and systemic inflammation that directly affects joint tissues — and chondroitin sulphate sits at a unique intersection of this pathway.

How chondroitin connects gut and joint health

Oral chondroitin sulphate has relatively low bioavailability — estimated at 5–15% in dogs.⁸ ¹¹ While this has traditionally been viewed as a limitation, emerging research reveals that the substantial proportion of CS that reaches the colon intact serves a biologically meaningful function as a substrate for gut bacteria.⁷ A systematic review by Shmagel et al. (2019) found moderate-quality evidence that CS supplementation alters gut microbial composition, including increased abundance of the genus Bacteroides — bacteria that play important roles in regulating microbial community balance and host health.⁷ CS and glucosamine are also important structural components of intestinal mucin, the protective barrier between gut flora and the intestinal wall, potentially affecting gut permeability and intestinal immune function.⁷

This means that chondroitin supplementation operates through a dual mechanism: direct chondroprotective effects from the absorbed fraction, and prebiotic-like gut microbiome modulation from the unabsorbed fraction. This dual action connects joint supplementation directly to the gut–joint axis framework.

GreenDroitin®’s relevance to the gut–joint axis

GreenDroitin®’s superior intestinal absorption profile has an interesting implication for the gut–joint axis. While enhanced absorption means more CS reaches the bloodstream and joint tissues (beneficial for direct chondroprotective effects), the proportion that remains in the gut — even if smaller than with conventional CS — still provides substrate for microbial metabolism. Additionally, the Tremella fuciformis-derived polysaccharides in GreenDroitin® have independently demonstrated gut microbiome-modulatory effects, including increased microbial diversity, enhanced short-chain fatty acid production and restoration of beneficial bacterial populations in preclinical models.¹²

The Segarra et al. (2016) canine IBD trial provides direct evidence that chondroitin sulphate combined with prebiotics can be safely and beneficially administered to dogs with inflammatory gastrointestinal conditions — supporting the broader principle that CS has meaningful biological activity in the canine gut.⁶

For a deeper exploration of the science connecting gut health to joint outcomes, see our article on the Gut–Joint Axis.

Why Bonza Uses GreenDroitin® in Bounce and Boost

Bonza’s decision to use GreenDroitin® rather than conventional animal-derived chondroitin reflects several converging principles that align with the company’s “One Gut. Whole Dog.” philosophy.

Formulation rationale

Bonza Bounce contains 80 mg of chondroitin sulphate from GreenDroitin® per chewy, while Bonza Boost contains 45 mg per chewy.³ These doses reflect the manufacturer’s data suggesting that GreenDroitin®’s enhanced absorption profile enables effective biological activity at approximately one-third of the dose required by conventional animal-derived CS sources.³ In practical terms, this means that the 80 mg in Bounce may deliver comparable or superior chondroprotective activity to 240 mg or more of conventional CS — a significant formulation advantage that allows meaningful dosing within a palatable, appropriately sized chewy format. The lower dose in Boost reflects its role as a comprehensive daily nutrition supplement rather than a dedicated joint-support supplement, while still providing meaningful chondroitin support as part of its broader whole-body formulation.

Synergy with Bounce’s formulation partners

In Bounce, GreenDroitin® (80 mg) works alongside a comprehensive suite of joint-support compounds that address different aspects of joint pathology simultaneously.³ Glucosamine HCl (240 mg) provides the biosynthetic substrate for GAG and proteoglycan synthesis — the building blocks of cartilage matrix. While glucosamine stimulates cartilage construction, GreenDroitin® inhibits its destruction through ADAMTS-5 modulation, creating a complementary push-pull mechanism.

MSM (120 mg) provides bioavailable sulphur essential for collagen cross-linking, connective tissue integrity and glutathione synthesis. Hyaluronic acid (5 mg) supports synovial fluid viscosity and joint lubrication. Avocado-soybean unsaponifiables (ASU, 10 mg) provide additional chondroprotective effects through distinct mechanisms including stimulation of chondrocyte collagen production.

Kynosil® (15 mg) delivers bioavailable silicon through patented mesoporous silica technology, supporting collagen synthesis and cross-linking in cartilage, bone and connective tissue. This creates a particularly effective partnership with GreenDroitin®: while GreenDroitin® inhibits ADAMTS-5-mediated cartilage degradation — protecting the existing cartilage matrix from enzymatic breakdown — Kynosil® provides the trace mineral substrate required for building and reinforcing new collagen structures within that matrix. The result is a protect-and-rebuild mechanism that addresses both sides of the cartilage turnover equation simultaneously.

The anti-inflammatory botanical complex — Boswellia serrata (10 mg), Curcuma longa (10 mg) and additional compounds — addresses the inflammatory cascade through complementary pathways: boswellia through 5-lipoxygenase inhibition and curcumin through NF-κB modulation.³

Synergy with Boost’s formulation partners

In Boost, GreenDroitin® (45 mg) is included as part of Bonza’s complete daily nutrition supplement, where it combines with glucosamine HCl (182 mg), N-acetyl-D-glucosamine (72.93 mg), MSM (90 mg), hyaluronic acid (7.5 mg), Boswellia serrata (15 mg), Curcuma longa (10.5 mg) and Zingiber officinalis (ginger, 15 mg).³

What makes Boost particularly noteworthy from a gut–joint axis perspective is the inclusion of Calsporin® (Bacillus velezensis, 75 mg) and Lactobacillus helveticus (5 mg) — direct probiotic support that complements chondroitin’s prebiotic-like microbiome effects.³ Because a meaningful proportion of orally administered chondroitin sulphate reaches the colon intact and serves as a substrate for gut bacteria,⁷ the presence of established probiotic strains in the same formulation creates a synergistic gut-health environment: GreenDroitin® feeds beneficial microbial activity while the probiotics help maintain the microbial community in which that activity occurs. This dual approach — combining structural joint support with direct gut microbiome support in a single daily supplement — reflects Bonza’s “One Gut. Whole Dog.” philosophy in its most integrated form.

The addition of ginger (Zingiber officinalis) in Boost provides further anti-inflammatory support through gingerols and shogaols, which inhibit COX-2 and 5-lipoxygenase pathways — complementing the NF-κB modulation provided by curcumin and the 5-lipoxygenase inhibition from boswellia.

Plant-based positioning

As a 100% plant-based (fungal-derived) ingredient, GreenDroitin® is consistent with Bonza’s commitment to formulating effective, science-led products without reliance on animal-derived ingredients wherever a credible plant-based alternative exists. For dogs with animal protein sensitivities or allergies — an increasingly common presentation in veterinary practice — a plant-derived chondroitin source eliminates the risk of introducing allergenic animal proteins through the supplement itself.

The sustainability advantage is equally meaningful. By sourcing chondroitin from cultivated Tremella fuciformis rather than animal cartilage, Bonza avoids contributing to the environmental pressures associated with shark harvesting and livestock-dependent supply chains.

Safety Profile

Tolerability

Chondroitin sulphate has a well-established safety profile across species, including dogs. The Segarra et al. (2016) canine IBD trial administered chondroitin sulphate with prebiotics for 180 days without reporting adverse effects.⁶ The broader canine literature on glucosamine–chondroitin supplementation consistently reports excellent tolerability, with the most commonly noted side effects being occasional mild gastrointestinal symptoms (soft stools) that are typically transient and self-resolving.¹⁴

The Galla et al. (2022) study specifically demonstrated that GreenDroitin® crosses the intestinal barrier without disrupting its integrity — an important safety finding that indicates it does not compromise gut barrier function during absorption.²

Allergenicity

One of GreenDroitin®’s most significant safety advantages is its suitability for dogs with shellfish, fish or animal protein sensitivities. Conventional chondroitin sourced from shark, bovine or porcine cartilage may introduce trace allergenic proteins that could trigger adverse reactions in sensitised dogs. GreenDroitin®’s fungal origin eliminates this concern entirely.

Tremella fuciformis itself has a long history of safe consumption as a food ingredient and has been classified as an edible medicinal mushroom with no significant reported adverse effects at normal dietary exposure levels.⁴

Contraindications

As with any form of chondroitin sulphate, caution is advised in dogs with known bleeding disorders or those receiving anticoagulant therapy, as CS has structural similarities to heparin and theoretical anticoagulant potential at very high doses.⁸ Dogs scheduled for surgery should discontinue CS supplementation 1–2 weeks beforehand as a precaution. Pregnant or nursing dogs should receive CS only under direct veterinary guidance, as safety data in these populations is limited.

As with all new functional supplements, consult your veterinarian before beginning GreenDroitin®-containing supplementation, particularly if your dog has a pre-existing health condition or is taking medication.

How to Support Your Dog’s Joint Health

A practical guide to incorporating GreenDroitin®-containing supplementation into your dog’s joint-health routine.

  1. Consult your veterinarian first.

    Before starting any joint supplement, discuss your dog’s specific needs — especially if they have a pre-existing condition, are on medication, or are a breed predisposed to joint issues.

  2. Start supplementation before clinical signs appear.

    Joint cartilage deterioration begins before visible symptoms emerge. Beginning chondroitin supplementation in adult dogs — from age 2–3 in large or predisposed breeds — provides structural support before significant cartilage loss occurs.

  3. Choose a supplement with verified, plant-based chondroitin.

    Select a product that declares the exact chondroitin content per serving from a traceable source. Bonza Bounce provides 80 mg of GreenDroitin® per chewy as part of a dedicated joint-support formulation, while Bonza Boost provides 45 mg per chewy alongside probiotics for combined joint and gut-health support.

  4. Supplement consistently — every day.

    Chondroitin works through cumulative mechanisms of enzyme inhibition, cartilage matrix support and microbiome modulation. Daily administration is essential; intermittent use will not allow tissue-level concentrations to build.

  5. Allow 6–10 weeks before evaluating results.

    Unlike NSAIDs, which suppress symptoms rapidly, chondroitin and its formulation partners build structural and anti-inflammatory effects gradually. Mark a date 8 weeks from starting and assess mobility, stiffness, comfort and activity levels at that point.

  6. Support the gut–joint axis.

    Because chondroitin acts partly through gut microbiome modulation, maintaining a healthy gut environment amplifies its systemic benefits. Ensure your dog’s diet includes prebiotic fibre, and consider a formulation that includes both joint-support and gut-health ingredients — Bonza Boost combines GreenDroitin® with Calsporin® and Lactobacillus helveticus probiotics for integrated gut–joint support.

  7. Maintain a healthy weight and appropriate exercise.

    Even the best supplementation cannot fully compensate for excess body weight placing additional mechanical stress on joints. Consistent, moderate exercise helps maintain joint mobility, muscle support and cartilage nutrition through synovial fluid circulation.

Frequently Asked Questions

Is GreenDroitin® as effective as animal-derived chondroitin?

The in vitro evidence published by Galla et al. (2022) in the Journal of Functional Foods indicates that GreenDroitin® achieves superior intestinal absorption compared with conventional animal-derived chondroitin sulphate and demonstrates comparable or enhanced chondroprotective effects, including ADAMTS-5 enzyme modulation in osteoarthritis models.² The manufacturer reports that GreenDroitin®’s absorption advantage enables effective results at approximately one-third of the dose of conventional sources.³ However, head-to-head clinical trials in dogs comparing GreenDroitin® directly with animal-derived CS have not been published — so while the laboratory evidence is promising, definitive in vivo comparative data is not yet available.

Is GreenDroitin® safe for dogs?

Chondroitin sulphate has a well-established safety profile in dogs, with multiple clinical trials reporting excellent tolerability over treatment periods of up to 180 days.⁶ ¹⁴ GreenDroitin® specifically was shown in the Galla et al. (2022) study to cross the intestinal barrier without disrupting its integrity.² Its fungal origin eliminates the allergenicity concerns associated with animal-derived CS sources. As with any supplement, consult your veterinarian before starting supplementation, particularly for dogs with bleeding disorders, those on anticoagulant medications, or pregnant or nursing dogs.

What is the difference between GreenDroitin® and glucosamine?

GreenDroitin® provides chondroitin sulphate, while glucosamine is a separate amino sugar — they are different molecules with complementary mechanisms.¹ Glucosamine provides the biosynthetic substrate (raw material) for constructing glycosaminoglycans and proteoglycans in cartilage. Chondroitin sulphate inhibits the enzymes that break down these structures. Used together, they create a synergistic effect: glucosamine promotes cartilage synthesis while chondroitin protects against cartilage degradation. This is why effective joint formulations — including Bonza Bounce — include both ingredients.

Can GreenDroitin® help with arthritis in dogs?

The evidence supports chondroitin sulphate as part of a multi-modal approach to managing canine osteoarthritis. The McCarthy et al. (2007) canine clinical trial demonstrated statistically significant improvements in pain, weight-bearing and overall condition with glucosamine–chondroitin supplementation.¹ GreenDroitin® delivers chondroitin sulphate with demonstrated superior absorption and chondroprotective activity in vitro.² It should be viewed as one component of comprehensive arthritis management, alongside appropriate veterinary care, weight management, exercise modification and potentially other supplements or medications.

Is GreenDroitin® vegan and plant-based?

Yes. GreenDroitin® is derived from Tremella fuciformis, an edible fungus (technically a member of the kingdom Fungi, which is biologically separate from both animals and plants). It contains no animal-derived ingredients and is suitable for vegan formulations. While fungi are not technically plants in the botanical sense, the term “plant-based” is widely used in the supplement industry to distinguish non-animal sources, and GreenDroitin® is marketed as a plant-derived ingredient by its manufacturer, Vivatis Pharma GmbH.

How does GreenDroitin® compare with other vegan chondroitin alternatives?

Several vegan chondroitin alternatives exist in the supplement market, including Mythocondro® (produced through E. coli fermentation by the Italian firm Gnosis) and Phytodroitin™ (derived from seaweed extracts by ProTec Nutra). GreenDroitin® differs in its source organism (Tremella fuciformis fungus rather than bacteria or algae), its patented extraction process (non-fermentation), and its published in vitro evidence demonstrating superior intestinal absorption.² Each alternative represents a different approach to solving the same problem — producing chondroitin sulphate without animal sources — and the optimal choice depends on the specific evidence base, quality data and formulation requirements.

How long does it take for GreenDroitin® to work?

Chondroitin sulphate — regardless of source — works through cumulative mechanisms rather than providing immediate symptom relief. The McCarthy et al. (2007) canine trial showed statistically significant improvements by day 70, with the authors recommending a minimum monitoring period of 70 days.¹ Most veterinary guidelines suggest allowing 6–10 weeks of consistent daily supplementation before evaluating results. GreenDroitin®’s superior absorption may support more efficient tissue-level accumulation, but the fundamental biology of cartilage repair and enzyme modulation still requires sustained supplementation over weeks to months.

Does GreenDroitin® support gut health as well as joints?

There is emerging evidence that chondroitin sulphate functions as a prebiotic-like substrate in the gut, with a systematic review finding moderate-quality evidence for microbiome-modulatory effects including increased Bacteroides abundance.⁷ Additionally, the parent compound Tremella fuciformis polysaccharides have demonstrated direct gut-health benefits in preclinical models, including restoration of microbial diversity, increased short-chain fatty acid production and enhanced intestinal barrier protection.¹² This dual activity — direct joint support from absorbed CS plus gut health benefits from the gut-microbiome interaction — connects GreenDroitin® supplementation to the gut–joint axis.

References

  1. McCarthy G, O’Donovan J, Jones B, McAllister H, Seed M, Mooney C. Randomised double-blind, positive-controlled trial to assess the efficacy of glucosamine/chondroitin sulfate for the treatment of dogs with osteoarthritis. Veterinary Journal. 2007;174(1):54–61. doi:10.1016/j.tvjl.2006.02.015
  2. Galla R, Ruga S, Ferrari S, Saccone S, Saccuman L, Invernizzi M, Uberti F. In vitro analysis of the effects of plant-derived chondroitin sulfate from intestinal barrier to chondrocytes. Journal of Functional Foods. 2022;98:105285. doi:10.1016/j.jff.2022.105285
  3. Vivatis Pharma GmbH. GreenDroitin® product documentation. Hamburg, Germany. Available from: https://www.greendroitin.com/
  4. Rui S, et al. Structure, function and application of Tremella fuciformis polysaccharide: a review. Journal of Food Science. 2025. doi:10.1111/1750-3841.70494
  5. Ruan Y, Li H, Pu L, Shen T, Jin Z. Tremella fuciformis polysaccharides attenuate oxidative stress and inflammation in macrophages through miR-155. Analytical Cellular Pathology. 2018;2018:5762371. doi:10.1155/2018/5762371
  6. Segarra S, Martinez-Subiela S, Cerda-Cuellar M, Martinez-Puig D, Munoz-Prieto A, Rodriguez-Franco F, et al. Oral chondroitin sulfate and prebiotics for the treatment of canine inflammatory bowel disease: a randomized, controlled clinical trial. BMC Veterinary Research. 2016;12:49. doi:10.1186/s12917-016-0676-x
  7. Shmagel A, Demmer R, Knights D, Butler M, Langsetmo L, Lane NE, Ensrud K. The effects of glucosamine and chondroitin sulfate on gut microbial composition: a systematic review of evidence from animal and human studies. Nutrients. 2019;11(2):294. doi:10.3390/nu11020294
  8. du Souich P, García AG, Vergés J, Montell E. Immunomodulatory and anti-inflammatory effects of chondroitin sulphate. Journal of Cellular and Molecular Medicine. 2009;13(8A):1451–1463. doi:10.1111/j.1582-4934.2009.00826.x
  9. Nature’s Best. Plant-based chondroitin: sustainability and ethical sourcing. Available from: https://www.naturesbest.co.uk/corporate-responsibility/plant-based-chondroitin/
  10. Vivatis Pharma GBHE. Process for extracting a hyaluronic acid from a fungus, a hyaluronic acid of plant origin and use thereof. Patent WO2021/250566A1. Published 2021. Available from: https://patents.google.com/patent/WO2021250566A1/en
  11. Bali JP, Cousse H, Neuzil E. Biochemical basis of the pharmacologic action of chondroitin sulfates on the osteoarticular system. Seminars in Arthritis and Rheumatism. 2001;31(1):58–68. doi:10.1053/sarh.2000.24874
  12. Xu Y, Xie L, Zhang Z, Zhang W, Tang J, He X, Zhou J, Peng W. Tremella fuciformis polysaccharides inhibited colonic inflammation in dextran sulfate sodium-treated mice via Foxp3+ T cells, gut microbiota, and bacterial metabolites. Frontiers in Immunology. 2021;12:648162. doi:10.3389/fimmu.2021.648162
  13. Tan M, Dai C, Lu X, et al. Proliferation and anti-inflammatory effects of Tremella fuciformis polysaccharide on human chondrocytes. Science and Technology of Food Industry. 2024;45(1):1–8. doi:10.13386/j.issn1002-0306.2023060077
  14. Bhathal A, Spryszak M, Louizos C, Frankel G. Glucosamine and chondroitin use in canines for osteoarthritis: a review. Open Veterinary Journal. 2017;7(1):36–49. doi:10.4314/ovj.v7i1.6

Editorial Information

FieldDetail
PublishedFebruary 2026
Last UpdatedFebruary 2026 — Initial publication
Reviewed byGlendon Lloyd, Dip. Canine Nutrition (Dist.), Dip. Canine Nutrigenomics (Dist.)
Next ReviewAugust 2026
AuthorGlendon Lloyd
DisclaimerThis article is for educational purposes only and does not constitute veterinary advice. Always consult a qualified veterinarian before making changes to your dog’s diet or supplement regimen.

About the Author

Glendon Lloyd | Dip. Canine Nutrition (Dist.) | Dip. Canine Nutrigenomics (Dist.)

Founder, Bonza

Glendon Lloyd is a canine nutrition researcher specialising in nutrigenomics, gut microbiome science, and the therapeutic application of plant-based bioactive compounds. His work at Bonza is informed by his academic training in how nutrients influence gene expression, immune function, and the gut–organ axes that connect digestive health to whole-body wellbeing. Glendon reads 5–6 peer-reviewed studies weekly to ensure Bonza’s formulations and educational content reflect the most current evidence in canine nutritional science.

Read Glendon’s full bio and credentials →

About Glendon Lloyd Dip.Canine.Nutrition Dip.Dog.Nutrigenomics

I have had dogs from the day I was born. Much to my Mum's amusement, my Dad bought home Zetta, a beautiful corgi puppy , as his contribution to our new family!

Fast forward to 2018 and Catherine, my wife, and one of our dogs Poppy, were both diagnosed and treated for cancer within months of each other

Diet and its impact on health, cancer particularly, led me down a rabbit hole of discovery.

I consumed information voraciously - on our diets, our dogs' diets and the impact these have not just on health but also the health of our increasingly fragile planet.

I was humbled by the time and expertise given so freely by doctors and vets, canine nutritionists and scientists, academics and agronomists. The more I learned the more I understood there had to be a better way to improve not just our health but also our dogs and the planet's.

The result of my trip down that rabbit hole is Bonza, a plant-based dog food (and now supplements) that elevate our dogs' diet beyond simple nutrition to a diet that inspires a healthier everyday life for our dogs and the planet.

I am continually researching the nutritional impact our dogs' diets have on their health and wellbeing and the ingredients and nutrients we should include in, and exclude from, their food to deliver longer, healthier lives.

I am delighted that my trip down the rabbit hole has led to me completing a Diploma in Canine Nutrigenomics and a Diploma in Canine Nutrition being awarded a Distinction for both my coursework and theses!

ADD LIFE TO YOUR DOG'S YEARS

X